Ultime notizie per Coda Octopus Group (NASDAQ:CODA) Azioni

Coda Octopus Group

Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

CODA

RFIL

VNCE

XCUR

Coda Octopus, Exicure e altri titoli in movimento nel pre-market: ecco cosa aspettarsi oggi 16 settembre 2024.

Pre-market: 5 titoli da monitorare oggi, 16 settembre 2024

Coda Octopus Group Inc

Codan Ltd

Coda Minerals Ltd

Digital Ally (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) reported quarterly earnings of $1.41 per share. This is a 105.13 percent increase over losses of $(27.48) per share from the same period last year. The company reported $4.40 million in sales this quarter. This is a 20.42 percent decrease over sales of $5.53 million the same period last year.

DGLY

Digital Ally Q1 EPS $1.41 Up From $(27.48) YoY, Sales $4.4M Down From $5.53M YoY

Guggenheim analyst Steven Forbes reiterates Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) with a Buy and maintains $450 price target.

Price Target

Reiteration

Analyst Ratings

Guggenheim Reiterates Buy on Home Depot, Maintains $450 Price Target

WIIM

Garrett Motion shares are trading lower after the company announced a secondary offering consisting of 17 million shares.

Jefferies analyst David Chiaverini initiates coverage on Valley Ntl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLY#NASDAQ">VLY</a>) with a Hold rating and announces Price Target of $10.

Initiation

Jefferies Initiates Coverage On Valley Ntl with Hold Rating, Announces Price Target of $10

Dycom Industries shares are trading higher after the company reported better-than-expected Q1 financial results, issued Q2 sales guidance above estimates, and raised its FY26 sales guidance.

ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) reported quarterly losses of $(0.08) per share. This is a 11.11 percent increase over losses of $(0.09) per share from the same period last year. The company reported $6.42 million in sales this quarter. This is a 8.13 percent decrease over sales of $6.99 million the same period last year.

ECDA

ECD Automotive Design Q1 EPS $(0.08) Up From $(0.09) YoY, Sales $6.42M Down From $6.99M YoY

Guggenheim analyst John Difucci reiterates SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) with a Buy and maintains $28 price target.

Guggenheim Reiterates Buy on SentinelOne, Maintains $28 Price Target

Jefferies analyst David Chiaverini initiates coverage on Texas Capital Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) with a Hold rating and announces Price Target of $80.

TCBI

Jefferies Initiates Coverage On Texas Capital Bancshares with Hold Rating, Announces Price Target of $80

James Hardie Industries shares are trading lower after the company reported worse-than-expected Q4 revenue results.

Full Truck Alliance shares are trading lower. The company reported Q1 financial results.

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said he doesn't like ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>), adding that &#8220;<a href="https://www.benzinga.com/quote/ZIM/earnings">dividend is a sucker's play.&#8221;</a>
On the earnings front, the company posted quarterly earnings of $2.45 per share on May 19, beating the analyst consensus estimate of $1.87 per share. The company reported quarterly sales of $2.01 billion, also beating the analyst consensus estimate of $1.85 billion.
Cramer recommended not buying The Mosaic Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) because the stock is up too much. &#8220;A parabolic move. If I come in now, I think I am too late,&#8221; he added.
On May 6, Mosaic reported quarterly earnings of 49 cents per share, which beat the analyst consensus estimate of 45 cents per share. The company reported quarterly sales of $2.62 billion, which missed the analyst consensus estimate of $2.66 billion.
&#8220;It does seem to be dead money,&#8221; Cramer said when asked about Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>). &#8220;I don't see much happening in the veterinary or livestock market at this very moment that's going to help them.&#8221;
As per recent news, the animal health firm reported a first-quarter 2025 adjusted EPS of $1.48 on May 6, up from $1.38 a year ago and beating the consensus of $1.39.
Price Action:
<ul class="wp-block-list">
<li>ZIM shares fell 2.7% to settle at $18.85 on Tuesday.</li>
<li>Mosaic shares rose 0.5% to close at $35.53 during the session.</li>
<li>Zoetis shares fell 0.2% to settle at $163.65 on Tuesday.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45517463/top-2-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 2 Risk Off Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Photo: Shutterstock

Media

Jim Cramer Recommends Not Buying Mosaic, Doesn't Like This Industrial Stock

Mortgage rates have jumped to their highest level in three months as U.S. Treasury yields, driven by rising deficits and fiscal policy fears, push the 30-year benchmark <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45505333/investors-piled-into-long-term-treasury-etfs-ahead-of-moodys-downgrade-will-confidence-hold">above the critical 5% mark</a>.
According to the latest Mortgage Bankers Association report, mortgage application volumes in the U.S. dropped 5.1% for the week ending May 16, the steepest decline in a month.
The drop coincided with the 30-year fixed mortgage rate jumping 6 basis points to 6.92%, marking its highest level in three months.
The rise in borrowing costs tracked Treasury yields higher &#8220;with investors concerned about rising inflation and the impact of increasing deficits and debt", said Mike Fratantoni, MBA's chief economist.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/05/45537307/us-stocks-likely-to-open-lower-expert-says-tariffs-remain-a-headwind-but-tax-cut-and-easing-of-tensions-in-middle-east-could-propel-equities-closer-to-all-time-highs">US Stocks Likely To Open Lower, Expert Says &#8216;Tariffs Remain A Headwind&#8217;</a>
<h3 class="wp-block-heading">Why Are Treasury Yields Rising?</h3>
Yields on the 30-year Treasury bond soared to 5.02% on Wednesday, up by over 10 basis points from a week ago.
A recent downgrade by Moody's of U.S. sovereign debt after market close last Friday has added to the pressure, shaking investor confidence and pushing yields higher. 
Bondholders are pricing in higher risk premiums as the federal government accelerates deficit spending without clear offsetting revenue measures.
A new tax-and-spending bill backed by President Donald Trump and Republicans is adding fuel to bond market fears. According to the Tax Foundation, the legislation would reduce federal revenues by an estimated $4.1 trillion from 2025 to 2034.
With public debt nearing 100% of gross domestic product and the Congressional Budget Office projecting a 117% debt-to-GDP ratio by 2035, bond investors are beginning to push back, demanding higher compensation for holding U.S. Treasuries.
The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) is down 0.9% during Wednesday premarket trading in New York.
The world&#8217;s biggest bond fund has lost 9% since Trump won the elections in November 2024. 
<h3 class="wp-block-heading">Ed Yardeni Sounds The Alarm On Deficit Risks</h3>
Veteran market strategist Ed Yardeni, founder of Yardeni Research, sounded the alarm over the soaring U.S. budget deficit. 
"Budget deficits matter. That's especially so when they lead to higher interest rates, higher bond yields, and potentially higher inflation," Yardeni said in a note Wednesday. 
Yardeni highlighted that the bond market is reacting not just to headline deficits, but to the structure of the Trump&#8217;s fiscal plan.
&#8220;Trump 2.0&#8217;s tax and spending bill—now moving swiftly through Congress—packs a fiscal punch,&#8221; he added. 
While the bill includes new deductions and credits for lower-income families, the largest benefits accrue to middle-class households via broader standard deductions and lower tax rates. High-income earners see a mixed outcome, with gains offset by reduced exemptions.
Yet Yardeni said every household could feel the pinch if the tax bill drives up fiscal stress, interest rates and borrowing costs.
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45537306/google-unveils-total-reimagining-of-search-with-chatbot-style-feature-to-compete-with-openai">Google Unveils Total Reimagining Of Search With Chat-Bot Style Feature</a></li>
</ul>
Image: Shutterstock

Analyst Color

Government

Macro Economic Events

Regulations

Bonds

Treasuries

Econ #s

Economics

Real Estate

iShares Trust Barclays 20+ Year Treasury Bond Fund

5% Treasury Yields Are Back, And So Are Painful Mortgage Rates

UnitedHealth Group shares are trading lower after HSBC downgraded the stock from Hold to Reduce and cut its price target from $490 to $270.

Guggenheim analyst John Difucci reiterates Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Sell and maintains $130 price target.

PANW

Guggenheim Reiterates Sell on Palo Alto Networks, Maintains $130 Price Target

Management

MKTX

MarketAxess Holdings Appoints Dean Berry As Group COO And CEO Of EMEA & APAC

General

Conduit Pharmaceuticals Regains Nasdaq Compliance

Palo Alto Networks shares are trading lower following Q3 reported financial results. Additionally, Bernstein cut its price target on the stock from $29 to $25.

Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy.
We have received feedback from the Medicines &amp; Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) that dosing may continue uninterrupted in ENVISION, study SRP-9001-303. ENVISION is a global, randomized, double-blind, placebo-controlled Phase 3 study of ELEVIDYS in non-ambulatory and older ambulatory individuals with Duchenne.
About ELEVIDYS (delandistrogene moxeparvovec-rokl)
ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle.
In the U.S., ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age.
<ul>
<li>For patients who are ambulatory and have a confirmed mutation in the DMD gene</li>
<li>For patients who are non-ambulatory and have a confirmed mutation in the DMD gene.</li>
</ul>
The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Biotech

SRPT

Sarepta Provides Update On UK Dosing in ENVISION Study Of ELEVIDYS For Treatment Of Duchenne Muscular Dystrophy. Company Received Feedback From The Medicines And Healthcare Products Regulatory Agency In U.K That Dosing May Continue Uninterrupted In Envision, Study Srp-9001-303

AVL's industry-leading engineering services, combined with Jabil's extensive industrialization and manufacturing expertise, will enable vehicle manufacturers to accelerate time-to-market for complex powertrain, compute, and driver assistance technologies
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.jabil.com%2F%3Futm_medium%3Dpr%26utm_source%3Dpress-release%26utm_campaign%3Davl&amp;esheet=54258013&amp;newsitemid=20250521230081&amp;lan=en-US&amp;anchor=Jabil+Inc.&amp;index=1&amp;md5=d4451d416b64b2e67daa64642b856074">Jabil Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>), a global manufacturing solutions provider to market-leading automakers, today announced it has signed a memorandum of understanding (MOU) with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avl.com%2Fen-us%3Futm_medium%3Dpr%26utm_source%3Dpress-release%26utm_campaign%3Davl&amp;esheet=54258013&amp;newsitemid=20250521230081&amp;lan=en-US&amp;anchor=AVL&amp;index=2&amp;md5=5aa3aceda081192e464dbee42fb701f5">AVL</a> Software and Functions GmbH, the e-drive and software center of AVL List GmbH.
The collaboration combines AVL's expertise in product design, software, simulation, and testing with Jabil's decades of experience in value engineering, advanced IATF-certified manufacturing, and strategic global <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.jabil.com%2Fsolutions%2Fsupply-chain-management.html%3Futm_medium%3Dpr%26utm_source%3Dpress-release%26utm_campaign%3Davl&amp;esheet=54258013&amp;newsitemid=20250521230081&amp;lan=en-US&amp;anchor=supply+chain&amp;index=3&amp;md5=61c35fb13cf4d4aeb8cddc30eee5ad9f">supply chain</a> solutions.
The MOU reflects Jabil and AVL's willingness to work together to offer comprehensive solutions across the product development lifecycle for next-generation vehicle technology. Jabil and AVL's complementary capabilities will enable customers to reduce complexity and cost when developing innovative vehicle electronics, including powertrain and charging technology, sensor-based driver assistance systems, and other on-board compute and control products. The non-exclusive collaboration expands the companies' development network, adding value through their combined strengths for customers, OEMs, and Tier 1 suppliers.

Jabil Signs MOU With AVL Software And Functions GmbH To Enable Vehicle Makers To Accelerate Time-To-Market For Complex Powertrain, Compute, And Driver Assistance Technologies

Keybanc analyst Eric Heath reiterates Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Overweight and maintains $220 price target.

Keybanc Reiterates Overweight on Palo Alto Networks, Maintains $220 Price Target

Press Releases

Coda Octopus Group Announces Acquisition of Precision Acoustics Limited

Coda Octopus Group Announces that it has recently received an order for fifteen of its new generation F280® GNSS Aided Inertial Navigation Systems ("GNSS Aided INS") for Contract Value of $576,000

Coda Octopus Group Sets Fiscal Year 2023 Earnings Conference Call for Wednesday, January 29, 2025 at 10:00 AM Eastern Time

Coda Octopus Group Sets Fiscal Year 2024 Earnings Conference Call for Wednesday, January 29, 2025 at 10:00 AM Eastern Time

Coda Octopus Group Reports Fiscal 2024 Financial Results

Coda Octopus Group Sets Fiscal First Quarter 2025 Earnings Conference Call for Monday, March 17, 2025, at 10 a.m. Eastern Time

Coda Octopus Group Reports Fiscal First Quarter 2025 Financial Results

Coda Octopus Group Reports $1.3m Engineering Services Order

Coda Octopus Group Reports $1.4m Engineering Services Order

Coda Octopus Group Reports $1.5m Order for its Diver Augment Vision Display System (DAVD) Tethered Variant for new community of users

Astrotech

Electro-Sensors

Focus Universal

Frequency Electronics, Inc. - Common Stock

Frequency Electronics

Identiv

AEye

Interlink Electronics, Inc. - Common Stock

Interlink Electronics

LightPath Technologies, Inc. - Class A Common Stock

LightPath Technologies

908 Devices

MultiSensor AI Holdings, Inc. - Common Stock

MultiSensor AI Holdings

Maris Tech

Microvision

NOVONIX Limited - American Depository Shares

NOVONIX

Ouster

Research Frontiers Incorporated - Common Stock

Research Frontiers

SmartRent

Sono-Tek

ScanTech AI Systems

TROOPS

Unusual Machines

Vishay Precision Group, Inc. Common Stock

Vishay Precision Group

VerifyMe

Vuzix

Wrap Technologies

Zepp Health Corporation American depositary shares, each representing sixteen Class A ordinary shares

Zepp Health

Alliance Global Partners

Comments

Coda Octopus Group

Notizie

Ultime notizie per Coda Octopus Group (NASDAQ:CODA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO